The PRECONNECT study not only confirms neutropenia as a predictor of response in a large population and in routine practice, but also provides information on prognostic factors for neutropenia and severe neutropenia that may help guide individualised treatment in future (i.e. including the use of granulocyte-colony stimulating factor [G-CSF]). The gene discussed is CSF3; the disease is Decreased total neutrophil count.